Case Studies

Challenge: A VC investor wished to make an investment in a California-based preclinical biotechnology company with a discovery platform and novel T cell therapies for cancer and other diseases....

Challenge: In order to better review potential acquisition and licensing opportunities, a pharma company asked Alacrita to landscape the companies, medical devices, digital technologies, research...

Challenge: A clinical stage biotech company developing novel oncology treatments was planning a private funding round to progress the clinical development of its lead product. The biotech requested...

Challenge: A clinical stage pharma company with development and commercialization rights to a novel treatment for GI indications wanted to gain marketing authorization in Europe. However, the...

Challenge: A biopharma start-up developing a small molecule to treat a rare kidney disorder sought Alacrita’s advice on its Target Product Profile (TPP) and market attractiveness. Specifically, they...

Challenge: A leading European university identified a gene therapy for the treatment of haemoglobinopathies. Alacrita was asked to support the Principal Investigator (PI) in developing a Commercial...

Challenge: A biotech company developing improved versions of available chemotherapy drugs approached Alacrita for indication strategy support, seeking to sanity check and refine its current clinical...

Challenge: A biopharmaceutical company was seeking assistance to prepare a response to the FDA’s initial refusal of its orphan drug designation application for its novel CAR-T therapy intended for...

Challenge: An oncology biotech company with a proprietary therapeutics development platform technology was in the process of fundraising activities. The company's pipeline included three main...

Challenge: A clinical stage biopharma company developing a novel small molecule to treat a rare respiratory disorder had conducted an Advisory Board to finalize the design of later stage clinical...

Challenge: A biotechnology company developing novel multi-specific antibody therapeutics to treat a range of cancers asked Alacrita to develop valuations for its four leading assets, as well as...

Challenge: Our client was a biotechnology company focused on use of a proprietary nanotechnology invented to allow different combinations of drugs to be encapsulated in a single nanomedicine and...